Bio Path Holdings Inc (BPTH) News

Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

New hi 3.85 700k float

BPTH new 52 lo

BPTH under $5

Volatility

BPTH: effective Feb. 23,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

October 24, 2023

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:

Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

https://ih.advfn.com/stock-market/NASDAQ/bio-path-BPTH/stock-news/92348612/bio-path-holdings-to-host-virtual-key-opinion-lead

$BPTH

Agree! Looking good.
$BPTH

Holding up pretty nice

12? We’ll see.. maybe once they get approved!

$BPTH - #DDAmanda Video Analysis

#DDAmanda Halloween Special: https://DDAmanda.com/SignUpHalloween164.php



Z

$BPTH Finally I got answer where BPTH going. Here you are: Target price $12. 1,500.00% up from today. Reason: FDA approval for drug ”Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc 2. Also Oct 11. 2023 News

+++ #DDAmanda Chart on: $BPTH :

DDAmanda lets you find these early:



Z

Out, halted. Beware of a selloff folks

Boom

Good luck, I had this back in the day when it made that huge run. Been watching off and on.

Yea. Got in pretty low on the jump. Don’t have many shares. Thanks for the info

They are waiting on from FDA for Fast Track Designation, they applied back in August, so it takes 60 days after the request. Either there is leak somewhere out there or just hedge run. If there is news tomorrow, I expect a huge run, closed very strong after hours.

You know what the catalyst is?

BPTH will run big tomorrow.

Going crazy AH

Lol

OCG BPTH WTO

who’s responsible?

Here we go again lol

BPTH new 52 week low

I could buy controlling interest in this company for $2.4m. Fire the CEO. Phase II is years away from a successful P-3 double blind. Of which would cost $200m. What could happen here is a consortium could come in and buy up 50% of the shares then juice the pump and sell them at $3.00 a share. But yes. Looks absolutely terrible here.

BPTH new 52 Week low

Bingo

Don’t get shook here this thang will have it’s day soon atlesst 50% bag

Lol

Blood Bath Holdings.

$BPTH - 👆Up 20% Pre-Market/ Current Price $1.29
👉Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Anyway, pps has been climbing slowly & steadily the last month.

Anyone here still holding BPTH?

86,231 shares traded today.

BPTH $$$

BPTH

BPTH

kool i hope this start running fda clear

AH will be interesting not selling $$$$$

Nice

Tomorrow this blows right by $9

kool got filled 6.32 ??

Hasn’t been blood all day nothing but green $$$$$$

BLOOD EVRR

Cmon wtf

Back to 52wk high let’s goooo$$$

Breaking out today ENJOY$$$$!

Profitability
Profit Margin 0.00%
Operating Margin 0.00%

Management Effectiveness
Return on Assets -25.12%
Return on Equity -42.71%

Cash Flow Statement
Operating Cash Flow -9.17M
Levered Free Cash Flow -5.47M